Eli Lilly and Co (HAM:LLY) ROCE %: 50.08% (As of Mar. 2026)


HAM:LLY Eli Lilly and Co HAM:LLY
98 GF Score
Price €1,039.40
GF Value €1,212.75
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Eli Lilly and Co ROCE %?

Eli Lilly and Co HAM:LLY +3.96% 98 ROCE % is 50.08% as of Mar. 2026. GuruFocus rates HAM:LLY with a GF Score™ of 98/100 and a GF Value™ of €1,212.75 (Modestly Undervalued). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Eli Lilly and Co's annualized ROCE % for the quarter that ended in Mar. 2026 was 50.08%.

Eli Lilly and Co  (HAM:LLY) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Eli Lilly and Co ROCE % Related Terms

Eli Lilly and Co ROCE % Historical Data

* Premium members only.

The historical data trend for Eli Lilly and Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co ROCE % Chart

Eli Lilly and Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.84 22.31 29.49 39.82 44.47

Eli Lilly and Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.11 44.89 43.03 60.89 50.08
HAM:LLY
98GF Score
Eli Lilly and Co HAM:LLY
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eli Lilly and Co ROCE % Calculation

Eli Lilly and Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=25360.384/( ( (75172.825 - 27099.08) + (96054.504 - 30084.712) )/ 2 )
=25360.384/( (48073.745+65969.792)/ 2 )
=25360.384/57021.7685
=44.47 %

Eli Lilly and Co's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=33831.88/( ( (96054.504 - 30084.712) + (100838.24 - 31688.41) )/ 2 )
=33831.88/( ( 65969.792 + 69149.83 )/ 2 )
=33831.88/67559.811
=50.08 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 50.08% mean?
Eli Lilly and Co (HAM:LLY) has a ROCE % of 50.08% as of Mar. 2026.
Is Eli Lilly and Co's ROCE % too high?
Eli Lilly and Co's current ROCE % is 50.08%. The Drug Manufacturers industry median ROCE % is 7.00. Eli Lilly and Co's value of 50.08% is 615.9% above this industry median. Overall, Eli Lilly and Co has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's ROCE % compare to JNJ and ABBV?
Eli Lilly and Co's ROCE % of 50.08% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. Eli Lilly and Co's value of 50.08% is 615.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eli Lilly and Co's current ROCE % of 50.08% is 615.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eli Lilly and Co's current ROCE % is 50.08%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (HAM:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is €1,212.75, compared to a current price of €1,039.40 — trading 14.3% below its estimated fair value. The current ROCE % is 50.08% and 615.9% above the Drug Manufacturers industry median of 7.00. Eli Lilly and Co's overall GF Score™ is 98/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Eli Lilly and Co (HAM:LLY), the current ROCE % is 50.08% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eli Lilly and Co (HAM:LLY) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued. The current stock price of €1,039.40 is trading 14.3% below its estimated GF Value™ of €1,212.75. GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.

Key valuation signals for HAM:LLY:

  • ROCE %: 50.08%
  • GF Value™: €1,212.75 vs. price of €1,039.40 (14.3% below fair value)
  • GF Score™: 98/100 with 6 warning signs
  • Industry Position: 615.9% above the Drug Manufacturers median

No single metric tells the full story. See the HAM:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
98GF Score

Get the complete analysis for HAM:LLY

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1,039.40
Price
€1,212.75
GF Value